Filing Flows › Voyager Therapeutics (VYGR) › Q3 2026 › vs Q3 2025
Voyager Therapeutics (VYGR) Q3 2026 vs Q3 2025 (year over year)
Voyager Therapeutics's revenue fell $9.4M (-70%) from $13.4M in Q3 2025 to $4.0M in Q3 2026.
Voyager Therapeutics, Q3 2026: revenue $4.0M (-70% year over year), operating margin -658.2%, net loss $24.7M, operating cash flow −$19.7M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $4.0M | $13.4M | −$9.4M | -70% |
| Other income, net | $1.7M | $2.8M | −$1.0M | -37% |
| Net loss | $24.7M | $27.9M | −$3.2M | -11% |
| Costs & expenses | $30.5M | $44.0M | −$13.6M | -31% |
| Operating costs | $30.4M | $44.0M | −$13.5M | -31% |
| Income tax | $18K | $83K | −$65K | -78% |
| Research & development | $24.4M | $35.9M | −$11.5M | -32% |
| General & admin | $6.1M | $8.1M | −$2.0M | -25% |
| Operating cash sources | $24.7M | $27.9M | −$3.2M | -11% |
| Depreciation | $836K | $932K | −$96K | -10% |
| Share-based compensation | $2.6M | $3.5M | −$857K | -25% |
| Working capital & other | $1.6M | −$7.5M | $9.1M | — |
| Cash used in operations | $19.7M | $31.0M | −$11.4M | -37% |
| Net loss absorbed | $24.7M | $27.9M | −$3.2M | -11% |
Questions
How much did Voyager Therapeutics's revenue grow year over year in Q3 2026?
Voyager Therapeutics's revenue fell $9.4M (-70%) from $13.4M in Q3 2025 to $4.0M in Q3 2026.